TRDA
Entrada Therapeutics Inc
NASDAQ: TRDA · HEALTHCARE · BIOTECHNOLOGY
$14.50
+7.41% today
Updated 2026-05-01
Market cap
$503.12M
P/E ratio
—
P/S ratio
19.79x
EPS (TTM)
$-3.47
Dividend yield
—
52W range
$5 – $14
Volume
0.2M
Entrada Therapeutics Inc (TRDA) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | $18.24M | $43.53M | $305.83M | $252.06M | $469.19M | $526.32M |
| Cash & equivalents | $16.84M | $39.05M | $291.06M | $45.16M | $67.60M | $101.21M |
| Current assets | $17.44M | $39.95M | $298.70M | $209.88M | $369.77M | $440.04M |
| Total liabilities | $33.76M | $85.02M | $7.12M | $39.50M | $226.83M | $97.64M |
| Current liabilities | $1.92M | $3.36M | $6.72M | $21.97M | $158.80M | $39.48M |
| Long-term debt | — | — | — | — | — | — |
| Shareholder equity | $-15.52M | $-41.49M | $298.72M | $212.55M | $242.36M | $428.68M |
| Retained earnings | $-15.99M | $-42.51M | $-93.67M | $-188.28M | $-194.97M | $-129.34M |
| Accounts receivable | — | — | $872000.00 | — | $5.88M | $3.68M |
| Inventory | — | — | — | — | $1.00 | — |
| Goodwill | — | — | — | — | — | — |